Physician profile
Irfan Jawed
NPI 1356508501
$12,987.74
in general payments reported to CMS, 2019-2025
55 companies · $1,167 in 2025
The $1,167 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,120 · 2020: $897 · 2021: $986 · 2022: $1,113 · 2023: $567 · 2024: $1,138 · 2025: $1,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,666 · Consulting Fee: $175 · Education: $30.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,666.27 |
| Consulting Fee | $175.00 |
| Education | $30.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $4,197.47 | 2019-2025 | Opdualag, Opdivo |
| Astrazeneca Pharmaceuticals Lp | $3,117.98 | 2019-2025 | Calquence, Imfinzi |
| Novartis Pharmaceuticals Corporation | $610.39 | 2019-2025 | |
| Eisai INC. | $354.43 | 2019-2025 | |
| Amgen INC. | $324.06 | 2019-2023 | Kyprolis |
| Sobi, INC | $319.69 | 2022-2025 | |
| Aveo Pharmaceuticals, INC. | $287.94 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $285.26 | 2019-2025 | Ultomiris |
| Merck Sharp & Dohme LLC | $275.65 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $260.21 | 2020-2025 | Enhertu, Datroway |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.23 | 2019-2020 | |
| Pfizer INC. | $219.32 | 2019-2023 | |
| Incyte Corporation | $181.99 | 2020-2025 | Jakafi |
| Pharmaessentia USA Corporation | $170.57 | 2022-2025 | Besremi |
| Janssen Pharmaceuticals, INC | $143.11 | 2020-2022 |
Show all 54 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irfan Jawed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.